December 28, 2022
On November 17, 2022, a seminar for Japanese parliamentarians was hosted by the Drugs for Neglected Diseases initiative (DNDi), an international non-profit organization which is jointly promoting research and development for neglected tropical diseases (NTDs) with Eisai, and the Global Health Innovative Technology Fund (GHIT Fund), Japan's first public–private partnership aiming to contribute to global health via Japanese innovations, in Tokyo, Japan. Approximately 20 participants attended the seminar.
Sayoko Sasaki, Eisai’s Vice President in charge of ESG, gave a presentation at the seminar. She highlighted Eisai’s initiatives for lymphatic filariasis (LF) such as free provision of LF treatment and support for elimination activities in endemic areas. She also touched on our collaboration with global partners such as DNDi and GHIT Fund to develop new treatments for NTDs, and the significance of tackling global health challenges from the perspective of solving social issues and creating corporate value. To achieve elimination of NTDs by 2030 which is stated in Goal 3 of the United Nations’ Sustainable Development Goals (SDGs), we emphasized the importance of public-private partnership, establishment of a system that enables priority and flexibility in regulatory process for NTD treatments, promotion of Japanese innovation and continued support of Japanese government to strengthen healthcare in Asia and Africa.
Eisai strives to achieve social good in the form of relieving anxiety over health and reducing health disparities as well as create long-term corporate value. We position our efforts towards improving access to medicines including elimination of NTDs as an important business domain guided by our human health care (hhc) concept. Eisai will continue to strengthen multi-sectoral partnership to contribute to the elimination of NTDs and global health.